01:40 PM EDT, 08/07/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target to $205 from $186, 13.9x our FY 26 EPS, a discount to historical due to tariffs and research funding cuts. We revise our FY 25 EPS to $14.35 from $14.22 and FY 26's to $14.80 from $15.51. BDX posts FQ3 EPS of $3.68 vs $3.50, above consensus by $0.28. Revenues were $5.5B (+10.4% Y/Y), reflecting strong performance in BD Medical (+14% Y/Y) bolstered by the acquisition of Advanced Patient Monitoring and robust growth in international markets (+11%). However, the BD Life Sciences segment faced challenges, with revenues down 0.5% Y/Y due to lower demand for Covid-19 testing and reduced research funding impacting the Biosciences unit. Looking ahead, BDX raised its FY 25 EPS guidance to $14.30-$14.45, up $0.18 at the midpoint, given the strong quarter and growth opportunities ahead. BDX's strategic initiatives, including the planned combination of its Biosciences and Diagnostic Solutions business with Waters Corp., position it well for long-term value creation, in our view.